defibrillators, and cardiac resynchronization therapy pacemakers or defibrillators are used widely to treat severe arrhythmia or heart failure. 8 Each device is usually implanted subcutaneously around the subclavicular area. Some of these patients develop keloids or hypertrophic scars at the incisions used for implantation. 9, 10 In the keloid outpatient clinic in our department, we became aware that patients who had been administered β-adrenergic receptor blockers (β-blockers) tended to have better postoperative scar formation than those who had not. Therefore, because studies on the effect of β-blockers on scar formation have not yet been reported, the present case-control study was performed. In this study, patients with abnormal scars after implantation of cardiac devices were compared with patients with normal scars in terms of the frequency of β-blocker treatment. Our hypothesis was that the patients with abnormal scars would be less likely to be treated with β-blockers than the controls with normal scars.
PATIENTS AND METHODS

Study Design
This case-control study was conducted with the approval of the Ethics Review Board of Kyoto University Graduate School of Medicine, Kyoto, Japan (approval number E2448). Informed consent to participate in the study was obtained from all patients before the study commenced. The study was conducted according to the principles of the Declaration of Helsinki.
Patient Selection
Patients who had undergone implantation with pacemakers, implantable cardioverter defibrillators, and cardiac resynchronization therapy pacemakers or defibrillators at Kyoto University Hospital 7 to 23 months previously and who went to the outpatient clinic of the Department of Cardiovascular Medicine of the hospital for routine follow-up were approached in May to October of 2015 by plastic surgeons. The patients were not enrolled consecutively because the plastic surgeons were not present at all hours in the cardiology outpatient clinic. The implantations included both primary and exchange operations. Patients were excluded if they had developed an infection at the implantation incision site, had been administered β-adrenergic receptor agonists after device implantation, or refused or were unable to give consent. We also excluded patients with a history or family history of abnormal scars because there was a greater likelihood they had undergone abnormal scar treatments, such as with corticosteroids, tranilast (Kissei Pharmaceuticals, Matsumoto, Japan), or excisional surgery, than patients without such scars. The eligible patients were divided into two groups: the cases, who had developed abnormal scars at the implantation incision, and the controls, whose scars were normal.
Primary and Secondary Study Outcomes
The primary outcome was the rate of β-blocker administration in the case and control groups. β-Blocker administration was defined as treatment with β-blockers that started either before implantation or just after the date of implantation and continued until the scars were scored with the Kyoto Scar Scale in the present study. The patients in the non-β-blocker group did not use a β-blocker during the postoperative period. The β-blockers that were used by the patients in the present study were carvedilol, bisoprolol, and atenolol. The secondary outcome was the rate of antihypertensive medication (calcium channel blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers) in the two groups. This secondary outcome was selected because there is some evidence that hypertension promotes keloid development 11 and that antihypertensive treatments can reduce the progression of keloids.
12,13
Implantation Procedure
All patients underwent device implantation by cardiologists under general anesthesia in the same manner: the devices were implanted subcutaneously around the subclavicular area, after which the fat and dermal layers were sutured with 4-0 or 5-0 polydioxanone II absorbable surgical sutures (Ethicon, Inc., Somerville, N.J.).
Study Protocol
After patients provided informed consent, their postimplantation scars were photographed by a digital camera and the dimensions were measured (Fig. 1) . The patients were then asked about the subjective symptoms of the scars and their personal and family histories of keloids or hypertrophic scars. Other clinical information was collected from the medical records, including the primary disease that required cardiac device implantation, the medications received before and during the study period, the blood pressure at the time of hospitalization and discharge and before and after implantation surgery, and comorbidities.
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Identification of Abnormal and Normal Postimplantation Incision Scars
The Kyoto Scar Scale measures three objective symptoms (i.e., redness, hardness, and elevation) and two subjective symptoms (i.e., itching and pain) ( Table 1 ). The scores of the five symptoms are added together to yield the total score ( Table 2) . 2 In this study, three board-certified plastic surgeons who were blinded to patient details assessed the digital photographs of the scars and diagnosed them as abnormal or normal using one element of the Kyoto Scar Scale (i.e., redness). This was because this is a variable that can be measured objectively on the basis of photographs. In the present study, all partially or totally red scars were deemed to be abnormal scars. All scars that lacked redness were considered to be normal scars. If the judgments of the three surgeons were not the same, the final diagnosis was based on the decision of the majority. The patients were then divided into the abnormal and normal scar groups on this basis. In addition, the total Kyoto Scar Scale score was calculated on the basis of all objective and subjective symptoms, as reported by the patients when they visited the clinic.
Classification of Blood Pressure
The blood pressure measurements at the time of hospitalization and discharge and before and Twelve months after her first cardiac resynchronization therapy defibrillator implantation, all three plastic surgeons diagnosed the scar as a normal scar. The total Kyoto Scar Scale score was 0 (excellent). She had been taking carvedilol 5 mg/day since implantation. (Below, right) Patient 52, a 77-year-old woman. Ten months after her first pacemaker implantation, all three plastic surgeons diagnosed the scar as a normal scar. The total Kyoto Scar Scale score was 0 (excellent). She had been taking bisoprolol 2.5 mg/day since implantation.
after implantation surgery were averaged and classified as optimal; normal; high-normal; or grade I, II, or III hypertension on the basis of 2014 Japanese Society of Hypertension guidelines (Table 3) .
Statistical Analyses
Continuous variables were expressed as mean ± SD if the distribution was normal, or as median (range) if the distribution was skewed. Categorical variables were expressed as number (percent). The abnormal scar cases and normal scar controls were compared in terms of continuous variables (i.e., age, postoperative period, scar length, mean blood pressure, and total Kyoto Scar Scale scores) using Wilcoxon rank sum test, and categorical variables (i.e., sex, type of β-blocker, number of implantation operations, type of cardiac device, and use of hypertensive medication) using Fisher's exact test. The cases and controls were also compared in terms of the frequency of β-blocker administration using univariate and multivariate logistic regression, which yielded odds ratios and 95 percent confidence intervals. The multivariate logistic regression was adjusted for age. All statistical analyses were performed using JMP Pro statistical software version 12 (SAS Institute, Inc., Cary, N.C.). Statistical significance was set at p < 0.05.
RESULTS
Subjects
Sixty patients were identified during the study period. Of these, 15 were excluded because they had developed an infection at the implantation incision site after surgery (n = 1), they had a personal (n = 9) or family (n = 2) history of keloids or hypertrophic scars, or they had been administered β-adrenergic receptor agonists after device implantation (n = 3). The remaining 45 patients were included in this study. Of those, 12 had abnormal scars, as defined by three plastic surgeons on the basis of scar redness. Thus, the study consisted of 12 cases and 33 controls (Fig. 2) .
Characteristics of the Case and Control Patients
Comparison of the case and control groups in terms of their demographic, clinical, and scar characteristics showed that the cases were significantly younger in terms of age at scar diagnosis (67.5 ± 10.0 years versus 78.3 ± 10.2 years; p = 0.0020). The two groups did not differ in terms of gender distribution; time since implantation; frequency with which pacemaker, implantable cardioverter defibrillator, or cardiac resynchronization therapy pacemaker or defibrillator was implanted; or mean scar length (Table 4 ). All implantation operations were performed by one of five surgeons. The cases and controls did not differ in terms of the frequencies with which each surgeon performed the surgery (data not shown). They also did not differ in terms of the frequency of the two main primary diseases that required cardiac device implantation (i.e., atrioventricular block and sick sinus syndrome). The two groups also did not differ significantly in terms of representative comorbidities (i.e., malignancy and diabetes mellitus) ( Table 4) . Various other complications, such as dyslipidemia, angina pectoris, respiratory disease, and renal dysfunction, Plastic and Reconstructive Surgery • May 2017 occurred in the two groups at similar frequencies (data not shown). As expected, the cases had a significantly higher mean total Kyoto Scar Scale score than the controls (2.50 ± 1.78 versus 0.03 ± 0.17; p < 0.001) ( Table 4) . The case and control groups did not differ significantly in terms of the frequency with which the β-blocker was carvedilol, bisoprolol, or atenolol (Table 5) . They also did not differ in terms of the frequency of patients who underwent cardiac device implantation for the first time (50 percent versus 72.7 percent) or the second, third, or fourth time. The mean number of operations for the two groups was 1.92 ± 1.08 and 1.42 ± 0.75, respectively (Table 6 ).
Primary Study Outcome: Frequencies of β-Blocker Use
Overall Postoperative Period The patients with abnormal scars tended to take β-blockers less often than the controls (25.0 percent versus 45.5 percent), but this difference did not achieve statistical significance on univariate logistic regression (OR, 0.40; 95 percent CI, 0.08 to 1.62; p = 0.2058) or multivariate logistic regression adjusted for age (OR, 0.43; 95 percent CI, 0.07 to 2.06; p = 0.2992) ( Table 7) . To assess whether the widely ranging duration after implantation (7 to 23 months) limited our ability to detect an association between abnormal scarring and low use of β-blockers, we performed the same analysis with our patients using narrower durations after implantation. 8 to 23, 9 to 23, 10 to 23, 11 to 
Scar Diagnosis
23, or 12 to 23 Months after Device Implantation
In 10 cases and 29 controls, the scars were diagnosed 8 to 23 months after implantation. Of these, one (10.0 percent) and 13 (44.8 percent) took β-blockers, and this difference achieved statistical significance on univariate logistic regression (OR, 0.14; 95 percent CI, 0.01 to 0.87; p = 0.0334) and multivariate logistic regression adjusted for age (OR, 0.10; 95 percent CI, 0.00 to 0.83; p = 0.0309). Similarly, in nine cases and 29 controls, the scars were diagnosed 9 to 23 months after implantation. Of these, one (11.1 percent) and 13 (44.8 percent) took β-blockers, respectively. This difference also achieved statistical significance on univariate logistic regression (OR, 0.15; 95 percent CI, 0.01 to 1.00; p = 0.0499) and multivariate logistic regression adjusted for age (OR, 0.11; 95 percent CI, 0.00 to 0.98; p = 0.047). These associations were no longer observed in patients whose scars were diagnosed 10 to 23, 11 to 23, or 12 to 23 months after implantation, even though, in each comparison, only one case took β-blockers, whereas nearly half of the controls took β-blockers (Table 8) .
Secondary Study Outcome: Frequencies of Antihypertensive Medication Use
The two groups did not differ in terms of mean systolic blood pressure (125.2 ± 6.6 mmHg versus 125.6 ± 15.3 mmHg), but the abnormal scar patients had significantly lower diastolic blood pressure (66.4 ± 8.1 mmHg versus 69.3 ± 10.1 mmHg; p = 0.048). Neither group had patients with grade II or III hypertension. The two groups did not differ significantly in terms of the frequency of patients with optimal/normal blood pressure, high-normal blood pressure, or grade I hypertension ( Table 9 ). The two groups also did not differ in the frequency with which they received calcium channel blockers and/or angiotensin receptor blockers, or angiotensin-converting enzyme inhibitors (Table 10) .
DISCUSSION
To our knowledge, this is the first time the putative association between β-blocker administration and reduced keloid or hypertrophic scar formation has been investigated by an observational study. Our results support the hypothesis that β-blockers could prevent or ameliorate keloids and hypertrophic scars after surgery: the patients who had keloids or hypertrophic scars after cardiac device implantation tended to be less likely to take β-blockers than the control patients with normal scars. This difference achieved statistical significance in patients whose scars were diagnosed 8 to 23 or 9 to 23 months after surgery.
β-Blockers are classified into three subtypes on the basis of the adrenergic receptor that they inhibit, namely, β1, β2, or β3. The β1 receptor mainly affects cardiac function: it increases the power of myocardial contraction and cardiac output when it is stimulated. When the β2 receptor is stimulated, it induces vasodilation of the peripheral artery and bronchodilation. The β3 receptor relates to fat metabolism: when it is stimulated, brown adipocytes combust free fatty acids. 14 β-blockers antagonize these effects. At present, β1 and β2 adrenergic receptor antagonists are used clinically as β-blockers.
Although β-blockers are primarily used to manage cardiac arrhythmias and angina pectoris, other indications have also arisen. Of particular interest for the present study, Léauté-Labrèze et al. first reported in 2008 that the nonselective β-blocker propranolol improved infantile hemangiomas in their case series. 15 Thereafter, many case studies showed that propranolol or other β-blockers effectively treat infantile hemangiomas. [16] [17] [18] This effect may relate to the fact that vasodilation and vascular endothelial proliferation play an important role in vascular tumor growth. These phenomena are promoted by β-adrenergic receptor stimulation, as it induces nitric oxide synthesis by the vascular endothelium and therefore promotes vasodilation; it also activates proangiogenic factors such as vascular endothelial cell growth factor (VEGF), which induces vascular endothelial proliferation. β-Blockers are surmised to inhibit infantile hemangioma proliferation by blocking these effects. 19, 20 These observations are pertinent for keloids because, like vascular tumors, the fibroblasts in keloid lesions produce abundant amounts of Plastic and Reconstructive Surgery • May 2017 VEGF. 21, 22 In addition, Salem et al. reported that, when keloids are treated by intralesional steroid injection, the VEGF levels in the lesions drop. 23 Thus, β-blockers could theoretically prevent the development or progression of keloids by suppressing their VEGF production. It is also possible that β-blockers inhibit keloid cell proliferation because β-adrenergic receptor stimulation activates extracellular signal-related kinase, which inhibits apoptosis and/or accelerates inflammatory cell migration and cell proliferation. [24] [25] [26] In the present study, the patients received three types of β-blockers, namely, carvedilol, bisoprolol, and atenolol. Carvedilol is an α-and β-adrenergic receptor blocker that antagonizes β1 and β2 at a β1:β2 blocking ratio of 7:1. 27 Both bisoprolol and stenolol are selective β1-blockers with β1:β2 blocking ratios of 75:1 and 35:1, respectively. 28 In the present study, the cases and controls did not differ in the frequencies with which they were treated with the three β-blocker types. Thus, the effect of β-blockers on keloid development that we observed could not be attributed to a specific β-blocker.
We diagnosed the scars of our patients between 7 and 23 months after the implantation. The most ideal time point for this diagnosis would have been 1 year after surgery because even healthy scars can take up to 12 months to mature; moreover, diagnosing scars much later may fail to detect hypertrophic scars, as these scars tend to improve after several years. 29 Indeed, we found that the difference between the case and control groups in terms of β-blocker administration frequency became statistically significant only when the postoperative duration range was 1 to 2 years after cardiac device implantation. This may reflect 
